Allergan had a 6.3 percent drop in sales in the first quarter ended March 31 to $994.6 million. This translated to a 0.4 percent drop in constant currencies. Eye-care pharmaceuticals fell by 3.8 percent (or grew by 2.3 percent at constant currencies) to $473.6 million. Earnings for the three months ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.